Analyzing the clinical benefit of newer therapies for advanced or metastatic non-small-cell lung cancer: application of the ESMO-magnitude of clinical benefit scale v1.1

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts & figures 2020. Am Cancer Soc. 2020;17–21.
   Google Scholar
• Naci H, Davis C, Savović J, et al. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis. BMJ. 2019;366:l5221.
   PubMed Web of Science ®Google Scholar
• Hilal T, Gonzalez-Velez M, Prasad V. Limitations in clinical trials leading to anticancer drug approvals by the US food and drug administration. JAMA Intern Med. 2020;180(8):1108–1115.
   PubMed Web of Science ®Google Scholar
• Hwang T, Ross J, Vokinger K, et al. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. BMJ. 2020;371:m3434.
   PubMed Web of Science ®Google Scholar
• Prasad V, De Jesús K, Mailankody S. The high price of anticancer drugs: Origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017;14(6):381–390.
   PubMed Web of Science ®Google Scholar
• Goulart BHL. Value: the next frontier in cancer care. Oncologist. 2016;21(6):651–653.
   PubMed Web of Science ®Google Scholar
• Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2015;26(8):1547–1573.
   PubMed Web of Science ®Google Scholar
• Cherny NI, Dafni U, Bogaerts J, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017;28(10):2340–2366.
   PubMed Web of Science ®Google Scholar
• Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33:2563–2577.
   PubMed Web of Science ®Google Scholar
• Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American society of clinical oncology value framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34(24):2925–2933.
   PubMed Web of Science ®Google Scholar
• Kiesewetter B, Raderer M, Steger GG, et al. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. ESMO Open. 2016;1(4):e000066.
   PubMed Web of Science ®Google Scholar
• Davis C, Naci H, Gurpinar E, et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ. 2017;359:j4530.
   PubMed Web of Science ®Google Scholar
• Fernández-López C, Calleja-Hernández MÁ, Balbino JE, et al. Trends in endpoint selection and result interpretation in advanced non-small cell lung cancer clinical trials published between 2000 and 2012: a retrospective cohort study. Thorac Cancer. 2019;10(4):904–908.
   PubMed Web of Science ®Google Scholar
• Broekman KE, Jalving M, van Tinteren H, et al. Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer – ESMO-MCBS scores. Cancer Treat Rev. 2018;69:233–242.
   PubMed Web of Science ®Google Scholar
• Del Paggio JC, Azariah B, Sullivan R, et al. Do contemporary randomized controlled trials meet ESMO thresholds for meaningful clinical benefit. Ann Oncol. 2017;28(1):157–162.
   PubMed Web of Science ®Google Scholar
• Del Paggio JC. Toxicity adjustment in the ESMO-MCBS: a gestalt approach? Ann Oncol. 2018;29(2):520–521.
   PubMed Web of Science ®Google Scholar
• Wild C, Grössmann N, Bonanno PV, et al. Utilisation of the ESMO-MCBS in practice of HTA. Ann Oncol. 2016;27(11):2134–2136.
   PubMed Web of Science ®Google Scholar
• Emprechtinger R, Grössmann N, Wild C. ESMO-MCBS v1.1: statistical and patient-relevant shortcomings. Ann Oncol. 2018;29(4):1070–1071.
   PubMed Web of Science ®Google Scholar
• Giuliani J, Remo A, Bonetti A. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations. Expert Rev Pharmacoecon Outcomes Res. 2017;17(1):5–8.
   PubMed Web of Science ®Google Scholar
• Hammerman A, Greenberg-Dotan S, Feldhamer I, et al. The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel. Expert Rev Pharmacoecon Outcomes Res. 2018;18(1):119–122.
   PubMed Web of Science ®Google Scholar
• Jönsson L, Sandin R, Ekman M, et al. Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation. Value Heal. 2014;17(6):707–713.
   PubMed Web of Science ®Google Scholar